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ABSTRACT
Purpose: The purpose of the current study was to explore if the laryngeal dose can be reduced
by using two Intensity-Modulated Radiation Therapy (IMRT) techniques: whole neck field IMRT
technique (WF-IMRT) vs. junctioned IMRT (J-IMRT). The effect on planning target volumes
(PTVs) coverage and laryngeal sparing was evaluated.
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Method: WF-IMRT technique consisted of a single IMRT plan including the primary tumor, the
superior and inferior neck to the level of the clavicular heads. The larynx was defined as an
organ at risk extending superiorly to cover the arythenoid cartilages and inferiorly to include the
crycoid cartilage. The J-IMRT technique consisted of an IMRT plan for the primary tumor and
the superior neck, matched to a conventional antero-posterior opposing lower neck fields at the
level of the thyroid notch. A central block was used for the anterior lower neck field at the level
of the larynx in order to restrict the dose to the larynx. Ten oropharyngeal cancer cases were
analyzed. Both the primary site and bilateral regional lymphatics were included in the
radiotherapy targets.
Results: The averaged V95 for the PTV57.6 was 99.2% for WF-IMRT technique when
compared with 97.4% (p=0.02) for J-IMRT. The averaged V95 for the PTV64 was 99.9% for
WF-IMRT technique when compared with 98.9% (p=0.02) for J-IMRT and the averaged V95 for
the PT70 was 100.0% for WF-IMRT technique when compared with 99.5% (p=0.04) for J-IMRT.
The averaged mean laryngeal dose was 18 Gy with both techniques. The averaged mean dose
within the matchline volumes were 69.3Gy for WF-MRT vs 66.2 Gy for J-IMRT (p=0.03).
Conclusion: WF-IMRT technique appears to offer an optimal coverage of the target volumes and a
mean dose to the larynx similar with J-IMRT and should be further evaluated in clinical trials.

INTRODUCTION
The optimal management of oropharyngeal cancer is multidisciplinary and radiotherapy is a part
of treatment approach for most of these patients. The greatest challenge with radiotherapy for
oropharyngeal cancer is to maximize loco-regional disease control, while minimizing the
morbidity and treatment-related toxicity to surrounding normal tissues, including the larynx [1].
With the development of the Intensity-Modulated Radiation Therapy (IMRT) technique, head
and neck cancers have been treated with good results as reported by various investigators [2,3].
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IMRT has been shown to offer better target homogeneity and tumor coverage and normal organ
sparing [3,4]. However, the use of IMRT tends to unnecessarily deliver higher dose to the larynx
[5]. More than one decade ago, Mendenhall et al. discouraged the practice of including the
uninvolved larynx in the radiation fields when the non-laryngeal primary tumor site could be
adequately covered by placing the inferior border of the opposed lateral fields at the level of the
thyroid notch. The superior section of the plan was matched to a conventional anterior neck field
resulting in very low doses to the larynx, which was typically blocked on the anterior field [1].
Emerging data from patients with long term follow up have showed that irradiation of the normal
larynx is associated with laryngeal dysfunction affecting patients’ quality of life in head and neck
cancer survivors, treated with radiation therapy [6,7]. Furthermore, recent studies by Eisburch et
al. have shown that sparing larynx improves dysphagia and aspiration [8].

The current study was undertaken to determine if the laryngeal dose can be reduced when
using IMRT techniques including the attempt to spare the larynx based on given dose
constraints for this organ at risk when a whole-neck field IMRT (WF-IMRT) is chosen or the use
of a junctioned IMRT (J-IMRT) consisting of an IMRT plan for the primary non-laryngeal tumor
and the superior neck, matched with a conventional opposed antero-posterior lower neck fields
at the level of the thyroid notch.

MATERIALS & METHODS
Patient Selection
Ten consecutive patients diagnosed with stage IV oropharyngeal squamous cell carcinoma and
treated between September 2006 and January 2007, at the University of Pennsylvania,
Department of Radiation Oncology were included in the current study. Approval was granted by
the Institutional Review Board for conducting this study. Nine patients were diagnosed with
stage IV A disease (T1-3N2bM0) and one patient with stage IV B disease (T2N3M0). The nodal
4

disease at the neck in four cases extended inferiorly to the level of the glottic larynx. All patients
were treated with IMRT to the primary site and the bilateral cervical lymph nodes. Two treatment
plans were generated for each patient using WF-IMRT and J-IMRT techniques and the
dosimetric data was compared between the two treatment plans. The coverage of the target
volumes and the dose to the larynx were compared using the resulting dose volume histograms
and the following dose parameters: V100 and V95 for the targets, and mean laryngeal dose.
V100 was defined as the percent of the target volume covered by 100% of the prescribed dose
and V95 was defined as the percent of the target volume covered by 95% of the prescribed
dose.

Radiotherapy treatment planning
All patients underwent a CT-based planning for IMRT using a 3 mm CT slice thickness to cover
the oropharyngeal tumors and bilateral cervical lymph nodes. Gross tumor volume (GTV) was
defined as the grossly visible tumor and metastatic lymphadenopathy on physical examination
and imaging studies (contrast CT and/or MRI). Clinical target volume (CTV1) encompassed the
GTV and the adjacent tissue supposed to contain microscopic, subclinical tumor extension and
first echelon nodes. The uninvolved nodal areas that were at lower risk of subclinical disease,
treated prophylactically were included in the CTV2 volume. Planning target volume (PTV) was
obtained by expansion of the CTVs to compensate for setup uncertainty, typically by 3-5 mm.
The PTV was adjusted appropriately, to respect the
anatomical bounders located in close proximity to the target volumes. Briefly, 70.4 Gy in 32
fractions were prescribed to the PTVs of the gross disease (PTV70.4), 64 Gy in 32 fractions to
the PTVs of high risk subclinical disease (subclinical disease at the surrounding area of the
primary tumor and first echelon lymph nodes) (PTV64), and 57.6 in 32 fractions to the PTVs
of the lesser risk sublicnical disease (the rest of the neck nodal targets) (PTV57.6),
respectively. All patients in this group were treated with a simultaneous in-field boost IMRT
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technique. Inverse treatment planning was performed using the treatment planning system
Eclipse v.8.10, anisotropic analytical algorithm (AAA). For each patient, a plan with 7-9 coplanar
sliding-window IMRT beams of 6MV was generated. The J-IMRT technique consisted of an
IMRT plan for the primary tumor and the superior neck above the level of the arythenoids. The
lower neck and the supraclavicular fossae were treated using a conventional half-beam blocked
antero-posterior opposing neck fields matched with the upper neck IMRT plan at the level of the
thyroid notch. A central block was used for the anterior lower neck field at the level of the larynx
in order to restrict the dose to this organ at risk, and a full central cord block was used for the
posterior field to protect the spinal cord. The upper neck IMRT was matched with the lower neck
field using a split-beam technique and there was no gap between the superior
IMRT fields and the inferior neck fields. Matchline volumes have been defined to include 3 mm
bellow and above the actual matchline for the PTVs and dose distribution has been evaluated in
this region. WF-IMRT technique consisted of a single IMRT
plan including the primary tumor, the superior and inferior neck to the level of the clavicular
heads, avoiding the matchline level present with J-IMRT technique. The larynx was
considered an organ of risk and was defined as superiorly covering the arythenoid cartilages
and inferiorly including the cricoid cartilage. The lateral borders of the planning organ at risk
volume (PRV) of the larynx were contoured 3-5 mm away from the medial borders of the neck
PTVs in order to avoid underdosage in these areas of the target volumes. Other organs at risk
included spinal cord (from the top of C1 vertebral body to approximately T3, just below the
lowest slice level that has PTV in it), brainstem, middle ears, bilateral parotid glands, mandible,
and the esophagus (from the bottom of cricoid cartilage to the thoracic inlet). The treatment
planning addressed the targets coverage objectives as the highest priority, whereas the organs
at risk dosimetric goals were secondary, with the exception of maximal spinal cord and braistem
dose. The dose constraints for the organs at risk are summarized in Table 1. Several iterations
were performed for optimization, aiming to reduce the mean dose to the larynx to the lowest
6

possible, while maintaining the target coverage and the constraints to the other organs at risk
according to the dose constraints and priority levels of the target volumes and organs at risk.

Dose-volume histograms
The dose-volume histograms (DVHs) of the target volumes and of the organs at risk were
analyzed with the emphasis on the target volumes coverage and the laryngeal dose.

Statistical methods
A Wilcoxon sign rank test was employed to determine if there was a statistically significant
difference between target coverage and laryngeal dose levels achieved for WF-IMRT versus
J-IMRT technique. In this study p-values less than 0.05 were considered significant.
RESULTS
The averaged V100 for the PTV57.6 was 97.7% for WF-IMRT technique when compared with
88.0% (p= 0.005) for J-IMRT, suggesting a better coverage of PTV57.6 by 100% isodose line
with WF-IMRT. The averaged V95 for the PTV57.6 was 99.2% for WF-IMRT technique when
compared with 97.4% (p=0.02) for J-IMRT. The averaged V100 for the PTV64 was 98.5% for
WF-IMRT technique when compared with 94.4% (p= 0.24) for J-IMRT. The averaged V95 for
the PTV64 was 99.9% for WF-IMRT technique when compared with 98.9% (p=0.02) for J-IMRT.
The averaged V100 for the PTV70 was 97.4% for WF-IMRT technique when compared with
94.1% (p= 0.12) for J-IMRT. The averaged V95 for the PT70 was 100.0% for WF-IMRT
technique when compared with 99.5% (p=0.04) for J-IMRT. Averaged dosimetrical parameters
to the target volumes and the organs at risk are represented in Table 2. The dose volume
histograms for the target volumes (PTV57.6) are represented in Figure 1a.
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The averaged mean laryngeal dose was 17.6 Gy for WF-IMRT technique when compared with
18.2 Gy (p= 0.44) for J-IMRT. See Table 2. The dose volume histograms for the larynx are
represented in Figure 1b.

Moreover, only 40 % of the laryngeal volume received approximately 18 Gy with both IMRT
techniques. Only 10% of the laryngeal volume receives > 20 Gy with WF-IMRT. See Figure 1b.

The averaged mean dose within the matchline volumes were 69.3Gy (SD +1.9) for WF-MRT vs
66.2 Gy (SD + 5.13) for J-IMRT (p=0.03).

DISCUSSION
The use of IMRT has been shown to unnecessarily distribute higher dose of radiation to the
larynx when the larynx sparing is not attempted as part of the IMRT treatment planning [5,9,10].
To avoid this situation, Amdur et al. used a J-IMRT technique with a superior-neck IMRT
matched with a conventional anterior lower neck field at the level of the thyroid notch, for
patients with non-laryngeal head and neck cancer. Amdur et al. demonstrated that the dose to
the normal larynx can be substantially reduced by shielding this organ on an anterior lower
neck field [5]. For the WF-IMRT that included both the primary site and the upper and lower
cervical lymph nodes, the mean laryngeal dose was 35 Gy in this study. This dose was much
higher than the mean laryngeal dose of 17 Gy obtained when the normal larynx was shielded
in the conventional anterior lower neck field by using a J-IMRT technique [5]. However, our
study revealed that the mean laryngeal dose may be significantly reduced using
WF-IMRT, when the larynx is defined as an organ at risk and is incorporated into the IMRT
optimization process, without compromising the target volumes coverage or the
accomplishment of dosimetric goals elsewhere in the treatment plan. The averaged mean
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laryngeal dose was 18 Gy using WF-IMRT, identical with the averaged mean laryngeal dose
achieved with J-IMRT. Furthermore, the current study results suggest that laryngeal doses
obtained by using WF-IMRT may be further reduced to values below 25 Gy previously reported
in the literature [11]. Webster et al. demonstrated that the dose to the larynx was decreased
significantly from a reported mean dose of approximately 45-50 Gy, usually described when
larynx sparing is not attempted with WF-IMRT, to a mean dose of 25-40 Gy if the larynx is
considered an organ at risk and is incorporated into the WF-IMRT optimization process [9-11].

Studies evaluating the dose distribution close to the matchline between the opposed lateral
fields and the anterior lower neck field as used by conventional radiotherapy for the treatment of
non-laryngeal head and neck cancers showed that there may be a few millimeters of increased
or decreased dose at or near field junction in the neck [12]. The clinical significance of these
dosimetric findings remains unclear. Bubenzer et al. showed, using thermolaminescent
dosimetry measurements on a Rando phantom, that the dose homogeneity along the matchline
and critical structures are of concern if the upper head and neck fields were treated with IMRT
and the lower neck with conventional (supraclavicular) fixed beam using a J-IMRT
monoisocentric technique similar to the one employed in our study [13]. The averaged mean
dose within the matchline volume were 69.3Gy for WF-MRT vs 66.2 Gy for J-IMRT (p=0.03) in
the present study.

Dose inhomogeneity across the matchline has been further investigated and new techniques to
mitigate the matchline dosimetrical uncertainties have been explored and reported in the
literature [14-16]. Amdur et al. reportedly move the upper border of the anterior lower neck field
few millimeters superiorly at least once during the radiotherapy treatment, in order to reduce the
dose inhomogeneity at the matchline between upper neck IMRT and conventional anterior lower
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neck field [14,15]. Furthermore, a dynamic supraclavicular field-matching technique for head
and neck cancer patients treated with IMRT has been developed by the same group [16].

Conclusions
Taking in consideration the limitation of the present study including a small number of patients,
our results suggest that the WF-IMRT technique may achieve an optimal coverage of the target
volumes and mean dose to the larynx similar with J-IMRT, while avoiding the dosimetric
uncertainty at the matchline present with J-IMRT. Clinical validation is required to determine
whether this dosimetric benefit can be translated into meaningful clinical gains for
oropharyngeal cancer patients.
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Table 1. Dose constraints for planning organ at risk volumes

PRV

Mean dose to the

Maximum dose to the

PRV (Gy)

PRV (Gy)

Spinal cord PRV

50

Brain Stem PRV

52

Parotid glands PRVs

26

Mandible PRV

70

Esophagus PRV

< 45

Larynx PRV

Reduce the dose as much as possible.

PRV, planning organ at risk volume
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Table 2. Averaged dosimetrical parameters to the target volumes and the organs at risk

Variable

WF-IMRT

J-IMRT

SD

p value

V100 for PTV70

97.4%

94.1%

1.69

0.12

V95 for PTV70

100%

99.5%

0.26

0.04

V100 for PTV64

98.45

94.4%

2.17

0.24

V95 for PTV64

99.9%

98.9%

0.43

0.02

V100 for

97.7%

88.0%

2.21

0.005

V95 for PTV57.6

99.2%

97.4%

0.59

0.02

Spinal cord

43.7 Gy

46.8 Gy

1.07

0.01

37.7 Gy

59.5 Gy

1.73

0.005

PTV57.6

maximum dose
Esophageal
maximum dose
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Lungs maximum

42.2 Gy

57.1 Gy

2.53

0.01

30.4 Gy

49.2 Gy

3.59

0.006

14.9 Gy

10.3 Gy

0.45

0.005

17.6 Gy

18.2 Gy

0.84

0.44

dose
Laryngeal
maximum dose
Laryngeal
minimum dose
Laryngeal mean
dose

Figure 1a. Dose-volume histogram for the target volumes (PTV57.6) using whole-neck field
IMRT (WF-IMRT) and junctioned IMRT (J-IMRT)
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Figure 1b. Dose-volume histogram for the larynx using whole-neck field IMRT (WF-IMRT) and
junctioned IMRT (J-IMRT)
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